Reportedly, Pharmacy chains Walgreen Boots Alliance (WBA) and CVS Health Corp (CVS) are limiting the purchase of children’s pain drugs as the retailers face supply constraints and high demand as the United States experiencing one of the highest and the worst flu seasons in a decade. Walgreens has put a limit of six over-the-counter pediatric fever reducers per online transaction, and CVS is currently limiting a two-product limit on all children’s pain-relief products online and at all its pharmacy locations.
Walgreen Boots Alliance (WBA) is a pharmacy-led, health and well-being enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. To learn more about Walgreen Boots Alliance (WBA) and to continue to track its progress please visit the Vista Partners Walgreens Boots Alliance Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
DID YOU KNOW?
Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. The American Cancer Society (ACS) estimates that approximately 270,000 women will be diagnosed with breast cancer in the United States this year. It is the second leading cause of cancer death in American women. Intense research has resulted in a great deal of knowledge about breast cancer. The factors that increase breast cancer risk include lifestyle (e.g., poor diet, sedentary, moderate to excessive alcohol consumption), certain genetic factors and dense breast tissue. Many of these factors can be reduced by taking steps before cancer strikes (risk mitigation) by adopting a healthier life-style and getting routine screening (e.g., mammograms, tomeography) that is proportional to one’s risk. Although tamoxifen has been used to reduce breast cancer risk, it is not a widely accepted practice due to safety concerns. Once breast cancer is diagnosed, treatment plans can include surgery, radiation and/or chemotherapy. After the initial treatment, long term drug therapy can reduce the risk of new or recurrent cancer. Atossa Therapeutics (NASDAQ: ATOS) is a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and radiation-induced lung injury. They believe their innovative therapies can benefit cancer patients receiving radiation treatment and can transform breast cancer treatment – with the goal of preventing breast cancer from developing in the first place. They are developing a drug “(Z)-endoxifen” to reduce mammographic breast density and, for patients who have recently been diagnosed with the most common type of breast cancer, to reduce tumor activity prior to surgery.
View Atossa’s CEO, Dr. Steven Quay’s M.D., PH.D. TedX Talk “How to Be Smart When You’re Dense: Preventing Breast Cancer by 2030.”
Consider visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.
